AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	2729	28911-01-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: triazolam U-33,030 U 33,030 U33,030	A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Molecular weight: 343.21 Formula: C17H12Cl2N4 CLOGP: 2.62 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 43.07 ALOGS: -4.27 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

triazolam
U-33,030
U 33,030
U33,030

A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Molecular weight: 343.21
Formula: C17H12Cl2N4
CLOGP: 2.62
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 43.07
ALOGS: -4.27
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.25	mg	O
0.20	mg	SL

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	44 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.58 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.70 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.473		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.698		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	65.464	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	22.646	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	15.760	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	39.290	%	High	1
herg	hERG pIC50	4.698	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	5.675	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	41.976	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	17.280	%	High	1
kinase-safety-class	ACVR2B,AXL,EIF2AK3,GRK2,ITK,MAPK10,MAPK7,PDK4,PIK3CG	9
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.159		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	38.637		High	1
mppb	Mouse plasma protein binding (% unbound)	19.200		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	9.886		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	24.960	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	131.522	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	67.330	%	High	1
rppb	Rat plasma protein binding (% unbound)	19.310	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	197.242	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Nov. 15, 1982	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	840.91	19.07	225	7201	24419	90596602
Drug abuse	634.82	19.07	242	7184	82105	90538916
Intentional self-injury	238.98	19.07	90	7336	29244	90591777
Overdose	152.22	19.07	116	7310	157593	90463428
Intentional overdose	144.52	19.07	92	7334	93742	90527279
Suicide attempt	141.81	19.07	84	7342	75315	90545706
Loss of consciousness	94.94	19.07	84	7342	140154	90480867
Completed suicide	90.54	19.07	83	7343	144975	90476046
Toxicity to various agents	86.60	19.07	112	7314	287734	90333287
Hemianopia	85.11	19.07	22	7404	2060	90618961
Coma	84.79	19.07	60	7366	72572	90548449
Alcohol interaction	54.88	19.07	15	7411	1739	90619282
Drug interaction	53.00	19.07	87	7339	276366	90344655
Corneal epithelium defect	50.77	19.07	11	7415	480	90620541
Anterior chamber cell	46.34	19.07	11	7415	725	90620296
Punctate keratitis	45.48	19.07	11	7415	785	90620236
Syncope	40.38	19.07	52	7374	132611	90488410
Torsade de pointes	39.62	19.07	21	7405	15161	90605860
Purpura senile	37.72	19.07	9	7417	606	90620415
Bradyphrenia	36.55	19.07	16	7410	7596	90613425
Hypokinesia	36.19	19.07	20	7406	15677	90605344
Corneal oedema	35.99	19.07	11	7415	1890	90619131
Altered state of consciousness	34.36	19.07	25	7401	31507	90589514
Hepatic function abnormal	33.83	19.07	29	7397	46259	90574762
Tarsal tunnel syndrome	33.10	19.07	8	7418	569	90620452
Application site injury	32.93	19.07	5	7421	26	90620995
Hyponatraemic encephalopathy	32.45	19.07	7	7419	299	90620722
Somnolence	31.21	19.07	59	7367	209025	90411996
Joint swelling	30.48	19.07	3	7423	503297	90117724
Hyporesponsive to stimuli	29.10	19.07	9	7417	1608	90619413
Bradykinesia	28.54	19.07	13	7413	6775	90614246
Electrocardiogram QT prolonged	27.89	19.07	32	7394	72424	90548597
Application site ulcer	27.28	19.07	5	7421	91	90620930
Resorption bone increased	27.17	19.07	8	7418	1211	90619810
Drug dependence	26.95	19.07	21	7405	29306	90591715
Vestibular disorder	25.28	19.07	8	7418	1541	90619480
Blood creatine phosphokinase increased	24.22	19.07	21	7405	34002	90587019
Intentional product misuse	23.98	19.07	33	7393	89571	90531450
Cerebral haemorrhage	23.95	19.07	21	7405	34501	90586520
Drug intolerance	23.88	19.07	4	7422	447587	90173434
Skin fissures	23.81	19.07	17	7409	20792	90600229
Postoperative delirium	23.24	19.07	5	7421	211	90620810
Intellectual disability	22.48	19.07	7	7419	1279	90619742
Labelled drug-drug interaction issue	22.32	19.07	8	7418	2250	90618771
Hypersensitivity	22.28	19.07	5	7421	454672	90166349
Hallucination, visual	22.23	19.07	17	7409	23075	90597946
Electrocardiogram T wave inversion	21.86	19.07	9	7417	3674	90617347
Depressed level of consciousness	21.30	19.07	28	7398	72756	90548265
Neuroleptic malignant syndrome	21.22	19.07	14	7412	15082	90605939
Extrasystoles	21.18	19.07	10	7416	5647	90615374
Poisoning	21.12	19.07	14	7412	15203	90605818
Attention deficit hyperactivity disorder	20.76	19.07	9	7417	4175	90616846
Serotonin syndrome	20.38	19.07	20	7406	37867	90583154
Arthropathy	20.15	19.07	3	7423	366239	90254782
Hypoglycaemic coma	20.14	19.07	8	7418	2982	90618039
Swelling	19.76	19.07	5	7421	419053	90201968
Hyperventilation	19.54	19.07	10	7416	6718	90614303
Peripheral swelling	19.34	19.07	5	7421	413101	90207920
Dysarthria	19.19	19.07	23	7403	54459	90566562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	408.58	19.72	121	4911	13081	42603222
Drug abuse	256.41	19.72	157	4875	104614	42511689
Intentional overdose	95.49	19.72	65	4967	51391	42564912
Bradyphrenia	64.37	19.72	24	5008	5238	42611065
Alcohol interaction	63.42	19.72	19	5013	2116	42614187
Completed suicide	54.70	19.72	62	4970	96403	42519900
Drug dependence	54.49	19.72	37	4995	29057	42587246
Overdose	53.59	19.72	64	4968	105200	42511103
Suicide attempt	53.55	19.72	44	4988	46056	42570247
Intentional self-injury	50.79	19.72	28	5004	15174	42601129
Reduced facial expression	47.08	19.72	14	5018	1519	42614784
Toxicity to various agents	44.42	19.72	89	4943	229047	42387256
Dissociative disorder	43.34	19.72	11	5021	661	42615642
Depressed level of consciousness	42.03	19.72	39	4993	47931	42568372
Suicidal ideation	36.22	19.72	36	4996	48125	42568178
Hypokinesia	32.47	19.72	18	5014	9853	42606450
Altered state of consciousness	32.03	19.72	27	5005	29232	42587071
Eye haematoma	29.18	19.72	6	5026	139	42616164
Blood creatine phosphokinase increased	28.95	19.72	32	5000	48306	42567997
Somnolence	25.13	19.72	53	4979	141052	42475251
Dissociation	24.66	19.72	11	5021	3787	42612516
Loss of consciousness	24.30	19.72	41	4991	92313	42523990
Hypertensive crisis	24.05	19.72	15	5017	10191	42606112
Neuroleptic malignant syndrome	23.88	19.72	20	5012	21452	42594851
Mental impairment	23.85	19.72	16	5016	12301	42604002
Drug interaction	23.50	19.72	77	4955	266922	42349381
Thinking abnormal	23.39	19.72	13	5019	7148	42609155
Road traffic accident	21.68	19.72	18	5014	19075	42597228
Fear	20.64	19.72	14	5018	10951	42605352
Panic attack	20.55	19.72	14	5018	11031	42605272
Mental disorder	20.47	19.72	17	5015	18012	42598291

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	1167.30	17.67	335	11400	36211	110541353
Drug abuse	816.83	17.67	390	11345	177021	110400543
Intentional self-injury	276.56	17.67	115	11620	37314	110540250
Intentional overdose	219.95	17.67	150	11585	132351	110445213
Suicide attempt	183.36	17.67	122	11613	103272	110474292
Overdose	180.96	17.67	169	11566	233625	110343939
Completed suicide	130.37	17.67	144	11591	242237	110335327
Toxicity to various agents	117.09	17.67	194	11541	480361	110097203
Alcohol interaction	109.31	17.67	32	11703	3662	110573902
Loss of consciousness	106.14	17.67	117	11618	196189	110381375
Bradyphrenia	86.43	17.67	36	11699	11692	110565872
Drug dependence	74.36	17.67	53	11682	49967	110527597
Hemianopia	68.24	17.67	21	11714	2847	110574717
Drug interaction	66.81	17.67	157	11578	500026	110077538
Hypokinesia	62.40	17.67	35	11700	21791	110555773
Coma	59.78	17.67	68	11667	117801	110459763
Depressed level of consciousness	59.03	17.67	66	11669	112212	110465352
Somnolence	56.67	17.67	108	11627	297341	110280223
Corneal epithelium defect	55.75	17.67	14	11721	898	110576666
Altered state of consciousness	55.04	17.67	47	11688	57579	110519985
Punctate keratitis	51.89	17.67	14	11721	1190	110576374
Anterior chamber cell	51.70	17.67	14	11721	1207	110576357
Hyporesponsive to stimuli	47.75	17.67	16	11719	2844	110574720
Blood creatine phosphokinase increased	47.32	17.67	48	11687	73029	110504535
Hepatic function abnormal	44.39	17.67	51	11684	89244	110488320
Neuroleptic malignant syndrome	43.64	17.67	33	11702	34026	110543538
Dissociative disorder	42.19	17.67	12	11723	1239	110576325
Reduced facial expression	40.24	17.67	15	11720	3636	110573928
Corneal oedema	38.53	17.67	14	11721	3159	110574405
Electrocardiogram QT prolonged	36.32	17.67	51	11684	108909	110468655
Mental impairment	35.99	17.67	25	11710	22614	110554950
Joint swelling	35.82	17.67	3	11732	442842	110134722
Intentional product misuse	34.03	17.67	55	11680	132849	110444715
Torsade de pointes	33.70	17.67	24	11711	22576	110554988
Suicidal ideation	32.85	17.67	45	11690	93892	110483672
Application site injury	31.80	17.67	5	11730	25	110577539
Tarsal tunnel syndrome	31.44	17.67	8	11727	541	110577023
Confusional state	31.32	17.67	115	11620	468565	110108999
Purpura senile	30.54	17.67	8	11727	607	110576957
Hyponatraemic encephalopathy	28.82	17.67	7	11728	391	110577173
Vestibular disorder	26.06	17.67	10	11725	2622	110574942
Fall	25.56	17.67	129	11606	603353	109974211
Eye haematoma	25.47	17.67	6	11729	294	110577270
Hypersensitivity	25.13	17.67	6	11729	403992	110173572
Bradykinesia	24.75	17.67	15	11720	10773	110566791
Application site ulcer	24.64	17.67	5	11730	121	110577443
Heat illness	24.04	17.67	7	11728	785	110576779
Hypertensive crisis	23.51	17.67	20	11715	24352	110553212
Drug intolerance	23.46	17.67	7	11728	406505	110171059
Resorption bone increased	23.32	17.67	8	11727	1526	110576038
Rhabdomyolysis	23.23	17.67	44	11691	120357	110457207
Miosis	23.20	17.67	19	11716	21964	110555600
Dysarthria	23.16	17.67	36	11699	84085	110493479
Syncope	23.16	17.67	60	11675	202476	110375088
Rheumatoid arthritis	21.75	17.67	3	11732	299610	110277954
Peripheral swelling	21.50	17.67	8	11727	404026	110173538
Cerebral infarction	21.48	17.67	27	11708	51811	110525753
Fatigue	21.05	17.67	63	11672	1215895	109361669
Interstitial lung disease	21.04	17.67	46	11689	139288	110438276
Swelling	20.34	17.67	6	11729	351035	110226529
Drug ineffective	20.23	17.67	88	11647	1520452	109057112
Urinary incontinence	19.64	17.67	25	11710	48562	110529002
Activation syndrome	19.14	17.67	5	11730	375	110577189
Hypoglycaemic coma	18.94	17.67	10	11725	5523	110572041
Panic attack	18.71	17.67	19	11716	28921	110548643
Delirium	18.62	17.67	43	11692	134982	110442582
Off label use	18.07	17.67	90	11645	1500095	109077469
Attention deficit hyperactivity disorder	17.93	17.67	9	11726	4482	110573082
Intellectual disability	17.76	17.67	7	11728	1972	110575592
Disturbance in attention	17.72	17.67	27	11708	61968	110515596

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CD05	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
FDA EPC	N0000175694	Benzodiazepine
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35717	sedative

Related Drugs by ATC class:

N05CD Benzodiazepine derivatives 14 drugs

brotizolam cinolazepam doxefazepam estazolam flunitrazepam flurazepam loprazolam lormetazepam midazolam nimetazepam nitrazepam quazepam show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Insomnia	indication	193462001
Suicidal thoughts	contraindication	6471006
Alcohol intoxication	contraindication	25702006
Depressive disorder	contraindication	35489007
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypoalbuminemia	contraindication	119247004
Disease of liver	contraindication	235856003	DOID:409
Sleep automatism	contraindication	247962006
Syncope	contraindication	271594007
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.22	Basic
pKa2	4.62	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA A receptor alpha-5/beta-2/gamma-3	Ion channel	P31644 P47870 Q99928	GBRA5_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.70	WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2	Ion channel	P18507 P34903 P47870	GBRG2_HUMAN GBRA3_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.88	WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3	Ion channel	P34903 P47870 Q99928	GBRA3_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.11	WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3	Ion channel	P28472 P31644 Q99928	GBRB3_HUMAN GBRA5_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.70	WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2	Ion channel	P18507 P31644 P47870	GBRG2_HUMAN GBRA5_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.22	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.16	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.23	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.85	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.02	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3	Ion channel	P14867 P47870 Q99928	GBRA1_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.64	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2	Ion channel	P14867 P18507 P28472	GBRA1_HUMAN GBRG2_HUMAN GBRB3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.10	WOMBAT-PK	CHEMBL
GABA-A receptor	Ion channel	O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 Q16445 Q8N1C3 Q99928	GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.10	IUPHAR	CHEMBL
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	5.88	PDSP
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	4.27	WOMBAT-PK
Cholecystokinin receptor type A	GPCR		CCKAR_RAT		IC50	4.41	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		Ki	9.10	CHEMBL

External reference:

ID	Source
4018066	VUID
N0000146407	NUI
D00387	KEGG_DRUG
4018066	VANDF
C0040879	UMLSCUI
CHEMBL646	ChEMBL_ID
DB00897	DRUGBANK_ID
D014229	MESH_DESCRIPTOR_UI
5556	PUBCHEM_CID
7313	IUPHAR_LIGAND_ID
3409	INN_ID
1HM943223R	UNII
10767	RXNORM
3103	MMSL
5618	MMSL
d00397	MMSL
001466	NDDF
111128007	SNOMEDCT_US
386984001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TRIAZOLAM	HUMAN PRESCRIPTION DRUG LABEL	1	16590-236	TABLET	0.25 mg	ORAL	NDA authorized generic	28 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-284	TABLET	0.25 mg	ORAL	ANDA	22 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-303	TABLET	0.13 mg	ORAL	ANDA	22 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43353-451	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	29 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0522	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	32 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6471	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7787	TABLET	0.25 mg	ORAL	ANDA	29 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50436-3718	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	28 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-645	TABLET	0.13 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-646	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3717	TABLET	0.13 mg	ORAL	NDA authorized generic	32 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3718	TABLET	0.25 mg	ORAL	NDA authorized generic	32 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	67544-725	TABLET	0.25 mg	ORAL	ANDA	23 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1289	TABLET	0.25 mg	ORAL	ANDA	29 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1521	TABLET	0.13 mg	ORAL	ANDA	29 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1162	TABLET	0.25 mg	ORAL	ANDA	2 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1576	TABLET	0.13 mg	ORAL	ANDA	2 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1876	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	72789-349	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	72789-349	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	82804-275	TABLET	0.25 mg	ORAL	ANDA	30 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

triazolam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: